M&As this week: Stryker, Merit Medical Systems, Johnson & Johnson

5 October 2018 (Last Updated October 5th, 2018 11:46)

Stryker has acquired HyperBranch Medical Technology for $220m in cash.

Stryker has acquired HyperBranch Medical Technology for $220m in cash.

Based in the US, Stryker is a medical technology company, while HyperBranch, also based in the US, is a medical device developer.

Merit Medical Systems has signed a definitive merger agreement with Cianna Medical.

The transaction includes an upfront payment of $135m, earn-out payments of up to $15m for achieving supply chain and scalability metrics, and up to $50m for reaching sales milestones.

The transaction is expected to close in the fourth quarter of this year, subject to regulatory approvals.

Merit plans to retain all of Cianna Medical’s commercial and research and development (R&D) teams and provide logistical and clinical support, following the completion of the transaction.

Based in the US, Merit is a manufacturer and marketer of proprietary disposable devices, while Cianna Medical, also based in the US, is engaged in the development of technologies for breast conservation.

Johnson & Johnson (J&J) has completed the divestment of its subsidiary LifeScan to Platinum Equity for approximately $2.1bn.

LifeScan is a Switzerland-based developer of blood glucose monitoring products.

Based in the US, J&J is a provider of medical devices, pharmaceuticals and consumer goods, while Platinum Equity, also based in the US, is a private equity investment firm.

“The acquisition will strengthen Hologic’s position in the breast-conserving surgery market by adding Focal Therapeutics’ BioZorb marker to its breast health products portfolio.”

J&J will provide products, services and solutions to diabetes patients through its Medical Device, Pharmaceuticals and Consumer businesses, following the divestiture.

Hologic has signed a definitive purchase agreement to acquire Focal Therapeutics in for $125m in cash.

The acquisition will strengthen Hologic’s position in the breast-conserving surgery market by adding Focal Therapeutics’ BioZorb marker to its breast health products portfolio.

BioZorb is an implantable, bio-absorbable, three-dimensional device, which has received the 510(k) clearance from the US Food and Drug Administration.

Based in the US, Hologic is a medical technology company, while Focal Therapeutics, also based in the US, is a medical device company.

Prima-Temp has acquired Kindara for an undisclosed sum.

The acquisition provides a proven platform and additional resources for the launch of Prima-Temp’s Priya Personal Fertility Sensor, which is expected to be launched globally next year.

Based in the US, Prima-Temp is a medical device manufacturing company, while Kindara, also based in the US, is a digital health company.